Statins Inhibit Inflammatory Cytokine Production by Macrophages and Acinar-to-Ductal Metaplasia of Pancreatic Cells

[1]  G. Bouche,et al.  Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway , 2021, Acta oncologica.

[2]  H. Crawford,et al.  Myeloid Cell Mediated Ilmmune Suppression in Pancreatic Cancer , 2021, Cellular and molecular gastroenterology and hepatology.

[3]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[4]  E. Olson,et al.  YAP/TAZ deficiency reprograms macrophage phenotype and improves infarct healing and cardiac function after myocardial infarction , 2020, PLoS biology.

[5]  Jin Ho Choi,et al.  The association between use of statin or aspirin and pancreatic ductal adenocarcinoma: A nested case‐control study in a Korean nationwide cohort , 2019, Cancer medicine.

[6]  Xin Tong,et al.  Inhibition of mutant Kras and p53‐driven pancreatic carcinogenesis by atorvastatin: Mainly via targeting of the farnesylated DNAJA1 in chaperoning mutant p53 , 2019, Molecular carcinogenesis.

[7]  G. Eibl,et al.  Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pancreatic ductal adenocarcinoma in KrasG12D mice , 2019, PloS one.

[8]  Chenyu Sun,et al.  Statin Use and Risk of Pancreatic Cancer: An Updated Meta-analysis of 26 Studies , 2019, Pancreas.

[9]  Y. Tsantrizos,et al.  Inhibition of farnesyl pyrophosphate (FPP) and/or geranylgeranyl pyrophosphate (GGPP) biosynthesis and its implication in the treatment of cancers , 2019, Critical reviews in biochemistry and molecular biology.

[10]  P. Kraft,et al.  Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  Craig M. Hales,et al.  Trends in Obesity and Severe Obesity Prevalence in US Youth and Adults by Sex and Age, 2007-2008 to 2015-2016 , 2018, JAMA.

[12]  H. Feng,et al.  Simvastatin accelerates hematoma resolution after intracerebral hemorrhage in a PPARγ-dependent manner , 2018, Neuropharmacology.

[13]  B. Spencer‐Dene,et al.  Duct- and Acinar-Derived Pancreatic Ductal Adenocarcinomas Show Distinct Tumor Progression and Marker Expression , 2017, Cell reports.

[14]  M. Milella,et al.  Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study , 2017, Scientific Reports.

[15]  Gang Li,et al.  Incidence of pancreatic cancer is dramatically increased by a high fat, high calorie diet in KrasG12D mice , 2017, PloS one.

[16]  A. Rustgi,et al.  Metaplasia: tissue injury adaptation and a precursor to the dysplasia–cancer sequence , 2017, Nature Reviews Cancer.

[17]  N. Bardeesy,et al.  The Presence of Interleukin-13 at Pancreatic ADM/PanIN Lesions Alters Macrophage Populations and Mediates Pancreatic Tumorigenesis. , 2017, Cell reports.

[18]  Bechien U. Wu,et al.  Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer , 2017, Journal of the National Cancer Institute.

[19]  P. Storz.  Acinar cell plasticity and development of pancreatic ductal adenocarcinoma , 2017, Nature Reviews Gastroenterology &Hepatology.

[20]  Yan-yan Su,et al.  Atorvastatin alleviates renal ischemia-reperfusion injury in rats by promoting M1-M2 transition. , 2017, Molecular medicine reports.

[21]  Peter Bankhead,et al.  QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.

[22]  B. Spencer‐Dene,et al.  YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK–STAT3 Signaling , 2016, Gastroenterology.

[23]  Shannon M. White,et al.  Yes-Associated Protein Mediates Immune Reprogramming in Pancreatic Ductal Adenocarcinoma , 2016, Oncogene.

[24]  Alberto Costa,et al.  Cancer Prevention and Interception: A New Era for Chemopreventive Approaches , 2016, Clinical Cancer Research.

[25]  E. Holly,et al.  Statin use and risk of pancreatic cancer: Results from a large, clinic‐based case‐control study , 2015, Cancer.

[26]  S. Dupont,et al.  The biology of YAP/TAZ: hippo signaling and beyond. , 2014, Physiological reviews.

[27]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[28]  A. Rosato,et al.  Metabolic control of YAP and TAZ by the mevalonate pathway , 2014, Nature Cell Biology.

[29]  B. Zetter,et al.  Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. , 2013, Cancer research.

[30]  Tingting Wang,et al.  Modulation of macrophage phenotype by cell shape , 2013, Proceedings of the National Academy of Sciences.

[31]  V. Fendrich,et al.  Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. , 2013, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[32]  J. Liao,et al.  Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL‐KrasG12D‐LSL‐Trp53R172H‐Pdx1‐Cre mice , 2013, Molecular carcinogenesis.

[33]  Gang Li,et al.  High-Fat, High-Calorie Diet Promotes Early Pancreatic Neoplasia in the Conditional KrasG12D Mouse Model , 2013, Cancer Prevention Research.

[34]  B. Necela,et al.  Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-κB and MMPs , 2013, The Journal of cell biology.

[35]  V. Steele,et al.  Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL‐KrasG12D/+ mice , 2012, International journal of cancer.

[36]  A. Malfitano,et al.  Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer , 2012, Pharmacological Reviews.

[37]  R. Newman,et al.  Differential Effects of Pravastatin and Simvastatin on the Growth of Tumor Cells from Different Organ Sites , 2011, PloS one.

[38]  E. Manser,et al.  Rho GTPases and their role in organizing the actin cytoskeleton , 2011, Journal of Cell Science.

[39]  J. Hogg,et al.  Effect of Atorvastatin on PM10-induced Cytokine Production by Human Alveolar Macrophages and Bronchial Epithelial Cells , 2009, International journal of toxicology.

[40]  M. Matsuda,et al.  Effects of Statins on Adipose Tissue Inflammation: Their Inhibitory Effect on MyD88-Independent IRF3/IFN-&bgr; Pathway in Macrophages , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[41]  Seppo Ylä-Herttuala,et al.  Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2. , 2008, Cardiovascular research.

[42]  P. Ridker,et al.  Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms , 2005, Nature Reviews Drug Discovery.

[43]  B. Necela,et al.  Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions. , 2015, Cancer discovery.